Sanofi’s (SNY) R&D Track Record Remains Investor Concern, Says BofA

Sanofi (NASDAQ:SNY) is among the 7 Oversold Pharma Stocks to Buy Now. Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA Sanofi (NASDAQ:SNY) is one of the most oversold stocks. TheFly reported that on February 20, SNY’s price target was lowered at Citi by EUR 5. On the other hand, earlier on February 12, BofA reduced its price target for SNY from EUR 102 to EUR 92 and downgraded the stock from Buy to Neutral. Following the announcement that Belén Garijo, the former CEO of Merck KGaA, wi ...